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The amyloid-β42 (Aβ42) peptide is believed to be the main culprit in the pathogenesis of Alzheimer 
disease (AD), impairing synaptic function and initiating neuronal degeneration. Soluble Aβ42 
oligomers are highly toxic and contribute to progressive neuronal dysfunction, loss of synaptic 
spine density, and affect long-term potentiation (LTP). We have characterized a short, L-amino acid 
Aβ-oligomer Interacting Peptide (AIP) that targets a relatively well-defined population of low-n 
Aβ42 oligomers, rather than simply inhibiting the aggregation of Aβ monomers into oligomers. Our 
data show that AIP diminishes the loss of Aβ42-induced synaptic spine density and rescues LTP in 
organotypic hippocampal slice cultures. Notably, the AIP enantiomer (comprised of D-amino acids) 
attenuated the rough-eye phenotype in a transgenic Aβ42 fly model and significantly improved the 
function of photoreceptors of these flies in electroretinography tests. Overall, our results indicate 
that specifically “trapping” low-n oligomers provides a novel strategy for toxic Aβ42-oligomer 
recognition and removal.
The amyloid-β 42 (Aβ 42) peptide is considered as the main culprit in the pathogenesis of Alzheimer 
disease (AD)1, postulated to impair synaptic function and initiate neuronal degeneration2,3. Though the 
evidence for a central role of Aβ in the pathogenesis is very strong4, other models support a modulatory 
function for low Aβ concentrations on neurotransmission and memory5,6.
Similar to other amyloid diseases, metastable oligomers and non-fibrillar amyloid intermediates can 
cause proteotoxicity in AD7. Intracellular tau, intracellular and extracellular Aβ can lead to cell death in 
vivo and in vitro8–12. Since soluble species of Aβ 42 are more strongly correlated with disease symptoms 
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compared to amyloid fibrils13, these toxic oligomers are believed to underlie losses in hippocampus syn-
apses (occurs early in the disease process) and correlate with the degree of cognitive impairment in AD 
patients14. Naturally secreted Aβ 42 oligomers can disrupt cellular models of learning and memory, hip-
pocampal long-term potentiation (LTP) in acute slices and in vivo, and impair the memory of a complex 
learned behavior in rats15. Usually, such studies have been conducted with higher concentrations while 
physiological concentrations are rather in the picomolar range and may have even beneficial effects6. 
Nevertheless, in vivo, Aβ is always a mixture of various aggregates, and a defined biological concentration 
of a specific oligomeric conformation has not been determined yet4.
Soluble low-n oligomers (i.e. tetramers and hexamers) of Aβ 42 are neurotoxic15,16 and ascribed to 
promote the progressive loss of dendritic spines and glutamatergic synapses17,18. It is plausible that the 
generation of toxic Aβ oligomers may be the result of newly formed aggregates, and/or the depolymeri-
zation of amyloid plaques. In either case, the cellular mode-of-action is not fully understood.
In the present study, we performed a peptide-based anti-amyloid approach, which differed from pre-
viously reported anti-oligomer strategies. A diverse array of biomolecules have already been identified 
which possess the ability to prevent amyloid fibril formation both in vitro and in vivo—large proteins 
such as molecular chaperones19, to small molecules such as flavonoids20, polyphenols21, hydroxyquino-
line derivatives22 and peptide-based inhibitors23–27. Preferably, the compound should neither be a dis-
sociation catalyst nor a monomer competitor but rather interact with potentially toxic Aβ oligomers 
to inhibit the conversion of low-n Aβ 42 oligomers into mature amyloid fibrils. Here, we demonstrate 
that an 8-residue long peptide (RGTFEGKF), initially designed on the framework GxFxGxF to disrupt 
sheet-to-sheet packings of Aβ 40 fibrils27 can specifically target low-n Aβ 42 oligomers (mainly tetramers 
and hexamers), rather than simply inhibit Aβ aggregation. Compared to earlier anti-amyloid oligomer 
strategies, AIP is unique in that this Aβ -oligomer Interacting Peptide (AIP) can “trap” toxic amyloid 
oligomers—i.e. inhibit the conversion of low-n Aβ 42 oligomers into mature amyloid fibrils, neutralize 
their toxicity and prevent the growth of Aβ oligomers into larger assemblies.
Results
Characterization of AIP on Aβ42 self-aggregation. To investigate the dynamics of Aβ 42 aggrega-
tion, the effect of AIP on fibril formation was first examined by transmission electron microscopy (TEM). 
After 24 hours incubation at room temperature, Aβ 42 wild-type (wt) peptides revealed well-structured, 
mature fibrils that were 18 nm wide and 300 nm long (Fig. 1A,B). In contrast, co-incubating Aβ 42 wt pep-
tides with AIP yielded protofibrillar-only structures and inhibited mature fibril formation (Fig. 1C). To 
further assess the targeting of Aβ 42 aggregates by AIP, we incubated Aβ 42 wt peptides for 4 or 12 hours 
prior to adding AIP, and then analyzed the aggregates for both time points after a total incubation period 
of 24 hours each. For the 4 hours/20 hours treatment, TEM analysis revealed oligomeric and protofi-
brillar structures without any Aβ 42 wt mature fibrils. Interestingly, the formation of mature fibrils was 
not abolished in the 12 hours/12 hours treatment (Fig. 1D) suggesting that AIP prevents Aβ 42 wt from 
undergoing structural transitions to a more compact form (i.e. characteristic of pre-fibrillar structures).
As an additional TEM control, we used the Aβ 42 G33A substitution peptide that is known to form 
oligomeric beta-pleated sheet complexes more readily than Aβ 42 wt peptide16 and stops aggregation at 
premature fibril stages due to its more hydrophobic surface. The Aβ 42 G33A peptides did not yield 
mature fibrils after 24 hours, (Fig. 1A), as expected, but we did observe protofibrillar structures that were 
smaller compared to Aβ 42 wt (average length of 100 nm versus 300 nm, respectively). In contrast, we did 
not observe any significant differences in protofibril width between Aβ 42 G33A and Aβ 42 wt (Fig. 1B).
Since TEM is limited in its deconvolution and magnification28, we also performed high-resolution 
atomic force microscopy (AFM) to further examine the influence of AIP on pre-fibrillar assemblies (i.e. 
protofibrils and oligomers). In the presence of AIP, the AFM analyses revealed globular particles and 
higher oligomeric structures with an average length of 100 nm for both Aβ 42 and Aβ 42 G33A peptides 
(Fig. S1). Validating our TEM data, this result implies that AIP might also affect oligomer formation at 
early stages of Aβ aggregation.
In order to acquire more detailed information at time points before fibrils are first observed, we per-
formed size-exclusion chromatography (SEC) using experimental conditions to match our corresponding 
microscopic analyses. When freshly dissolved Aβ 42 wt peptides were incubated for 0, 4, or 8 hours, slow 
oligomerization dynamics consistently yielded superimposable tetra-/hexamer oligomer peaks (Fig. 1E). 
The Aβ 42 G33A substitution peptide exhibited faster kinetics (Fig. 1F), immediately forming high-n oli-
gomers, which steadily increased over time, while the amount of tetra-/hexamers decreased. Thus, Aβ 42 
G33A exhibited a faster aggregation process over 8 hours compared to the wt peptide (Fig.  1F and E, 
respectively). When the identical Aβ 42 wt experiments were repeated in the presence of AIP, consistent 
kinetics yielded superimposable tetra-/hexamer oligomer peaks with only a modest increase in high-n 
oligomers (compare Fig.  1E with 1G). Co-incubating Aβ 42 G33A with AIP significantly reduced the 
formation of high-n oligomers over time while reducing the loss in low-n oligomers (compare Fig. 1F 
with 1H). Importantly, our findings establish that (i) the oligomer-stabilizing effect of AIP is stronger for 
the more aggregation-prone Aβ 42 G33A peptide16 compared to Aβ 42 wt, and (ii) AIP has a quantitative 
impact on oligomers in that it can attenuate the conversion of low-n tetra-/hexamers into high-n oli-
gomers. Moreover, AIP appears to interact with tetra-/hexameric Aβ complexes with a 1:1 stoichiometry 
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Figure 1. Aggregation studies of Aβ42 wt and Aβ42 G33A peptides. (A) TEM micrographs were acquired 
after 24 hours incubation. Aβ 42 wt aggregated to mature fibrils whereas Aβ 42 G33A solely formed globular 
oligomers and protofibrilar structures. Scale bar = 200 nm. The graphs in (B) depict the means ± SEM 
of fibril width (wt, n = 20; G33A, n = 17) and length (wt, n = 20; G33A, n = 17). ***p < 0.001, ns = not 
significant, Student’s t-test. (C) TEM micrographs showed that neither Aβ 42 wt nor Aβ 42 G33A formed 
mature fibrils when co-incubated with the AIP for 24 hours. (D) TEM analyses of Aβ 42 wt peptides 
aggregated for 4 and 12 hours before addition of AIP and subsequent mixture was incubated for 24 hours. 
AIP was capable to block fibril formation of Aβ 42 wt only when low-n oligomers had formed after 4 hours 
pre-incubation. AIP did not abolish fibril formation when higher aggregates or protofibrils were present 
(12 hours pre-incubation). (C,D) Scale bar = 100 nm. SEC analyses of aggregated Aβ 42 peptides within 
8 hours after freshly dissolving. (E) Aβ 42 wt peptides mainly existed as tetra-/hexamers whose amount 
slightly decreased over time whereas the quantity of high-n oligomers (16–20mers) slightly increased.  
(F) Aβ 42 G33A is presented by a higher amount of high-n oligomers, tremendously increasing over time. 
(G) Freshly dissolved Aβ 42 wt peptide (0 h), after 4 and 8 hours of co-incubation with the AIP showed a 
constant amount of tetra-/hexamers and only a slight increase of high-n oligomers. (H) Co-incubation of 
Aβ 42 G33A with the AIP abolished the shift from low aggregates to high-n oligomers over time. (I) AIP 
itself eluted from the column at 20 ml (for comparison see Fig. 1E,F).
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since we did not observe any other novel peaks eluting at different times. As an additional control, we 
confirmed that AIP elutes from the column in the salt fraction (Fig. 1I).
AIP inhibition of Aβ42-induced neurotoxicity. Since AIP was able to interact with low-n oli-
gomers and attenuate mature fibril formation in the experiments above, the effect of AIP on neurotox-
icity was then examined using MTT assays in SH-SY5Y cells. In the absence of AIP, freshly dissolved 
Aβ 42 wt peptides (pre-incubated for 4 or 8 hours) were able to reduce the number of living cells by 
approximately 40% (Fig. 2A); under similar assay conditions, the presence of AIP was able to neutralize 
the Aβ 42 wt-induced toxic effects. Likewise in MultiTox assays (Fig.  2B) where primary hippocampal 
neurons were pre-incubated with Aβ 42 wt in the absence and presence of AIP for 4 hours, AIP almost 
completely attenuated the Aβ 42-mediated loss of living cells. As a control, we also tested the non-toxic 
Aβ 42 G33A peptide16, which behaved similarly to Aβ 42 wt with AIP.
Given that soluble Aβ species can lead to dendritic spine loss29 and reduce spine plasticity at den-
drites17, we examined the effect of AIP on the excitatory synapse stability of dendritic spines in the pres-
ence of Aβ 42. Treating organotypic hippocampal slice cultures with Aβ 42 for 24 hours led to a significant 
(p < 0.05) reduction in the number of CA1 pyramidal cell dendritic spines compared to control slices 
(Fig.  3A,B; mean ± SEM of spine/μ m are as follows: control, 1.68 ± 0.17 spine/μ m; Aβ 42, 1.05 ± 0.07 
spine/μ m). Co-incubation with AIP, however, was able to prevent the Aβ 42-mediated CA1 spine density 
losses (AIP, 1.65 ± 0.12 spine/μ m vs. Aβ 42 + AIP, 1.71 ± 0.07 spine/μ m). Next, we investigated whether 
the significant decrease in spine density was subtype-dependent (i.e. thin, stubby, mushroom) in order 
to assess the number of glutamatergic α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic (AMPA)-type 
receptors and synapse strength30, i.e. larger spine heads favor the presence of more AMPA receptors and 
stronger synapses31. Importantly, mushroom and thin spine subtypes were affected by Aβ 42 treatment 
after 24 hours.
As LTP can be accompanied by structural modifications of dendritic spines, we next examined the 
effect of AIP on theta-burst stimulation (TBS)-induced LTP in the presence of Aβ 42 in the CA1 region 
of mouse hippocampal slices. In keeping with previous findings, Aβ 42 significantly inhibited LTP in 
the CA1 region of mouse hippocampal slices (Fig.  3C; p < 0.05), as compared to control (50 minutes 
post-TBS (mean ± SEM): control, 151 ± 21%; Aβ 42, 88 ± 13%). Under similar conditions, LTP was not 
decreased when Aβ 42 was co-incubated with AIP (50 minutes post TBS: AIP, 159 ± 30%; Aβ 42 + AIP, 
148 ± 14%). Figure 3D depicts averaged representative traces of field excitatory postsynaptic potentials 
(fEPSPs).
AIP affects the D. melanogaster rough-eye phenotype and electrophysiology. To assess the 
























































Figure 2. Cell viability of SH-SH5Y cells and primary hippocampal neurons after treatment with Aβ42 
peptides. (A) SH-SY5Y cells were treated with 4- or 8-hour pre-incubated Aβ 42 wt peptides (2.5 μ M), in 
the presence and absence of AIP. Shown are graphs depicting the mean ± SEM viability as a % normalized 
to vehicle-treatment. ***p < 0.001, One-way ANOVA and Dunnett’s post-hoc test (AIP treatment was used 
as control). Number of independent experiments in triplicate: Aβ 42 4 h, n = 4; Aβ 42 + AIP 4 h, n = 7; 
Aβ 42 8 h, n = 6; Aβ 42 + AIP 8 h, n = 8. (B) Hippocampal primary neurons were treated with 4-hour 
preincubated Aβ 42 wt or Aβ 42 G33A peptides, in the presence and absence of AIP. The viability (%) is 
shown as the mean ± SEM, normalized to vehicle-treated cells. **p < 0.01, One-way ANOVA and Dunnett’s 
post-hoc test (AIP treatment as control). Number of independent experiments in triplicate: Aβ 42 wt n = 11, 
Aβ 42 wt + AIP n = 5, Aβ 42 G33A n = 9, Aβ 42 G33A + AIP n = 6, AIP n = 6.
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strains expressing and secreting Aβ 42 in the eye invokes an abnormal “rough-eye” phenotype16,32. The 
extent of cell death can be determined by visual inspection of the eye morphology33 and the severity 
of the Aβ 42-induced toxicity can be estimated by the ratio of photoreceptors (rhabdomeres to omma-
tidia)16,32. TEM analysis of eye cross-sections from 5-day old non-transgenic flies revealed intact omma-
tidia with seven characteristic photoreceptor cells present (Fig.  4A). In contrast, TEM images from 
the Aβ 42-transgenic flies exhibited severe distortions in eye morphology (Fig.  4B); specifically, the 
“rough-eye” phenotype was characterized by significantly altered ommatidia (smaller and less expressed), 
where the photoreceptors are less expressed and rhabdomeres appear shrunken.
To test the effect of AIP, we carried out food supplementation studies, where Aβ 42-transgenic fly 
larvae were raised on food containing 5 mM AIP, which is a concentration that is in accordance to most 
studies examining the effects of drugs on flies34. Also, since living organisms typically catabolize L-amino 
acid-containing proteins, for these in vivo studies, we tested AIPs comprised of either L- (L-AIP) or 
D-amino acids (D-AIP). We found that AIP-treatment led to an attenuation of Aβ 42-induced toxicity 
but not a complete rescue. For the flies that consumed AIP composed of L-amino acids (L-AIP; Fig. 4C), 
there still was diminished expression of photoreceptors in all ommatidia, vacuoles could be found, 
and shrunken rhabdomeres. For D-AIP-raised transgenic flies (Fig.  4D), eye morphology dramatically 
improved, including ommatidia with up to seven characteristic rhabdomeres, however, vacuoles could 
























































Figure 3. Quantification of dendritic spines and LTP recordings of Schaffer collateral CA1 region 
following Aβ42 and Aβ42 with AIP treatments. (A) Representative 3D reconstructions of dendritic 
segments from organotypic hippocampal sister slice cultures that were treated either with Aβ 42 (1 μ M), AIP 
or Aβ 42 and AIP-containing media. Scale bar = 2 μ m. (B) There is a significant decrease in the densities for 
spine subtypes following Aβ 42 treatment compared to control. Treatment with Aβ 42 in conjunction with 
AIP did not affect spine density. Total dendritic segment lengths (mean ± SEM): Control, n = of 672 μ m 
from 12 cells in 4 cultures; Aβ 42, n = 795 μ m from 14 cells in 4 cultures; AIP, n = 884 μ m from 16 cells in 
4 cultures; Aβ 42 + AIP, n = 970 μ m of dendrite from 18 cells in 4 cultures. *p < 0.05, **p < 0.01 one way 
ANOVA with Tukey’s multiple comparison test was performed for each spine subtype (* refers to Aβ 42 vs. 
Aβ 42 + AIP). (C) AIP treatment in the presence of oligomeric Aβ 42 species prevented the decrease in LTP 
level following TBS. Shown are quantifications of fEPSPs from control, Aβ 42-, AIP-, and AIP + Aβ 42-treated 
slice cultures. Following 24 hours of Aβ 42 treatment (1 μ M), there was a marked decrease in LTP response. 
This deficit was prevented by AIP (AIP + Aβ 42). AIP alone did not have an effect on LTP. Control, n = 9 
slices; Aβ 42, n = 6 slices; AIP, n = 6 slices; AIP + Aβ 42, n = 6 slices; One-way ANOVA with Tukey post-
hoc comparison was used on the last time-point (*p < 0.05). fEPSP stimulus was delivered and recorded 
every 10 s; data points were averaged into five minute intervals for display and statistical analysis purposes. 
Averaged sample traces of fEPSPs obtained from control, Aβ 42-, AIP-, and AIP + Aβ 42-treated slice 
cultures are shown in (D). There was a marked decrease in the level of potentiation achieved following TBS 
stimulation. Black, baseline; grey, 50 minutes after TBS.
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effects on eye morphology (Fig. 4E). Since the D-AIP was significantly more effective at ameliorating the 
toxic phenotype, it can be regarded as a peptidomimetic—i.e. possessing similar selectivity and potency 
as the native L-AIP “parent”, as cross-validated in our in vitro systems (Fig. S2). The peptidomimetic 
was likely more effective in our Aβ 42-transgenic fly model since it has been reported that the D-amino 
acids are more protease-resistant (i.e. increased stability of AIP) as compared to their L-amino acid 
counterparts35,36.
To determine if the protective effect of D-AIP at the structural level (i.e. retinal morphology) trans-
lated to improved eye function in the treated Aβ 42-transgenic flies, we then recorded electroretinograms 
(ERGs). All photoreceptor cells respond to a simple light pulse with a short delay, followed by a sus-
tained depolarization (so-called “receptor potential”) that lasts as long as the stimulus37. The majority 
of the response is from photoreceptors R1-6 and their post-synaptic targets. Rhodopsin1 (Rh1) in R1-6 
responds broadly to light with a peak in the blue range, R8 rhodopsin overlaps well with the Rh1 spectral 
sensitivity, and UV sensitive photoreceptors (R7) fire least robust to this stimulus38. Recorded with an 
electrode in the distal retina and a reference electrode elsewhere in the body, the ERGs measured as a 
change in the voltage drop across the basement membrane. Our non-transgenic flies (Fig. 5A) generated 
typical ERG profiles: on-transient signal (mean ± SD: 5.45 ± 1.18 mV), followed by a receptor potential 
(6.75 ± 2.52 mV), and finally the negative off-transient signal (6.57 ± 1.69 mV). Aβ 42-expressing flies 
(i.e. transgenic; Fig. 5B) exhibited a significantly reduced response to light, as indicated by the missing 
on- and off-transient signals and receptor potential: 1.11 ± 1.06 mV, 0.94 ± 1.15 mV, and 0.94 ± 1.02 mV, 
respectively. Aβ 42 transgenic flies treated with L-AIP (Fig.  5C) generated ERG profiles similar to the 
untreated Aβ 42 flies (on-transient, 0.75 ± 0.68 mV; receptor potential, 1.16 ± 1.40 mV; off-transient, 
0.83 ± 0.97 mV). Remarkably, treatment with D-AIP (Fig.  5D) significantly increased their response to 
light, as indicated by the enhanced on- and off-transient signals, and receptor potential (2.97 ± 0.81 mV, 
3.72 ± 1.33 mV, and 4.56 ± 2.03 mV, respectively). Non-transgenic flies treated with D-AIP did not exhibit 
altered ERGs (Fig.  5E; on-transient, 5.88 ± 1.49 mV; receptor potential, 6.37 ± 1.18 mV; off-transient, 
7.58 ± 1.04 mV), as compared to our untreated, non-transgenic flies (Fig.  5A). Figure  5F displays the 
quantifications of the on- and off-transient signals, as well as the receptor potential for each sample 
group.
Analysis of AIP interaction with Aβ. Based upon our biophysical AIP data (TEM, AFM, SEC) and 
the Aβ 42 structure provided by Luhrs and colleagues39, we generated molecular docking models for both 
L-AIP (Fig. 6, Fig. S3, S4) and D-AIP (Fig. S5), and its interaction with Aβ 42 tetramers.
To predict how L-AIP might interact with Aβ 42 tetramers, 6 best-fit poses were generated (see 
Methods). A strong interaction was found between AIP-Arg1 and Asp23 of the terminal sheet. Due to a 
lateral shift within the Aβ 42 tetramer, Asp23 of the terminal sheet is unpaired, while within the oligomer 
it forms a salt bridge with Lys28 of the neighboring sheet promoting fibril growth (Fig. 6A, S3A). In our 
model, L-AIP-Arg1 replaces Lys28 in that interaction, implying an interference with the Asp23-Lys28 
salt bridge formation. The predominant configuration of L-AIP binding is with its C-terminal portion 
to the groove formed at Gly33 (Fig. 6A, see Fig. S4A–E). L-AIP-Arg1 extends down to Asp23, forming 
a strong hydrogen bond. Additional interactions are formed between Phe4 or 8 and Gly33 plus Met35 
(Fig. 6A; S4A–E). In a second binding mode, which is less frequently found, L-AIP binds to the Gly37 




tg Aβ42, L-AIPtg Aβ42, untreated tg Aβ42, D-AIP
E
non-tg, D-AIP
Figure 4. Ultrastructural analyses of retinas from Aβ42 wt-expressing D. melanogaster treated with 
AIP. Shown are representative electromicrographs of the ultrastructure of fly retinas in cross-section. Eyes 
of non-tg control flies showed a highly ordered structure of rhabdomeres and ommatidia (A). In contrast, 
flies expressing Aβ 42 wt (B) have a rough-eye phenotype, with pronounced malformed ommatidia and 
rhabdomeres. Aβ 42 wt tg flies raised on 5 mM L-AIP showed an improvement of rough-eye phenotype (C), 
but those raised on D-AIP (D) showed a far greater retention of ommatidia and rhabdomere structures, as 
compared to (B). (E) Treatment of non-tg control flies with D-AIP (5 mM) did not affect eye morphology. 
Scale bar = 5 μ m.
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Finally, docking of D-AIP to Aβ 42 (Fig. S5A–G) yielded similar binding modes and specific interac-
tions including the Arg1-Asp23 bond, as compared with the L-AIP (Fig. 6A) (Fig. S5A–C, and G). Due 
to the isomeric structure, however, we observe a slightly improved packing of D-AIP into each of the 
Gly grooves, forming similar interactions with Aβ 42 (Fig. S5D–F).
In our second analysis, we performed flexible docking of L-AIP to the substitution peptide Aβ 42 G33A 
to find a rationale for its faster aggregation and unique behavior compared to L-AIP (see Fig. 1E–H). The 
introduction of a methyl group to residue 33 changes the L-AIP binding to the Gly37 groove. Different 
interactions, including poses with reversed N- to C-terminal AIP topology (poses 1 and 2) are observed 
(Fig. S3B, S4G, H). As indicated in the third best-fit pose, configurations forming the Arg1-Asp23 hydro-
gen bond are still possible, although they less likely occur as with Aβ 42 (Fig. 6B, S4I).
The tetramer is the minimal unit required to meet the steric/spatial constraints imposed by the length 
of the peptidic molecule, which binds to the groove provided by Gly33 and simultaneously interacts with 
Asp23.
To provide further evidence of the physical interaction between AIP and Aβ 42 (as predicted by our 
SEC and molecular docking results), we performed limited proteolysis experiments. In brief, Aβ 42 was 
incubated with trypsin and aliquots taken at different time points were analyzed by MALDI mass spec-
trometry (MS) to test for the presence of specific cleavage products. In the absence of AIP, the cleav-
age of Aβ 42 generated Aβ 1–16 and Aβ 17–28 fragments and their corresponding C-terminal products 
(Fig. 7A), thus implying that this region is highly flexible and easily accessed by trypsin. To visualize the 
proteolytic time course, area under the curve of peaks from the acquired MALDI spectra were used to 
calculate the ratio of fragment Aβ 17–28 to uncleaved Aβ 42. Co-incubating Aβ 42 with either L- or D-AIP 
led to a significantly decreased ratio of Aβ 17–28 to Aβ 1–42, most likely by protecting the Aβ 42 peptide 
from trypsin by shielding the Lys28 cleavage site (Fig. 7C). Since AIP itself contains two basic residues 
(Arg in position 1 and Lys as the second last amino acid residue at the C-terminus), we also performed 
L- and D-AIP-only trypsin digestions (i.e. without Aβ 42) to ensure that AIP was not degraded during 
the three hour time-course (Fig.  7B). Overall, our proteolysis data (i.e. masking of Lys28 in Aβ 42 by 


















































Figure 5. ERG traces in D. melanogaster expressing Aβ42 wt in the presence and absence of AIP. Shown 
are representative ERG traces from non-tg (A) or tg Aβ 42-expressing flies in the absence (A,B) and presence 
of L-AIP (C), or D-AIP (D,E). (A) Untreated non-tg flies showed characteristic on- and off-transients, and 
receptor potentials. (B) Untreated tg Aβ 42 flies revealed reduced on- and off-transients, and diminished 
receptor potentials. (C) Tg Aβ 42 flies treated with 5 mM L-AIP exhibited almost no on- and off-transients, 
and no receptor potential. (D) Tg Aβ 42 flies treated with 5 mM D-AIP demonstrated a significant response 
to light compared to untreated tg Aβ 42 flies. (E) Non-tg flies treated with D-AIP showed no effect compared 
to untreated non-tg flies (A). Quantification of on- and off-transients, and receptor potential from each 
group are shown in (F). Data are represented as the mean ± SD of n = 6–10. **p < 0.01, ***p < 0.001, One 
way ANOVA with Tukey’s multiple comparison test.
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induced a more tightly packed Aβ 42 conformation that masks Lys2816. Accordingly, co-incubating Aβ 42 
G33A with L- or D-AIP did not significantly change the ratio of Aβ 17–28 to Aβ 1–42 G33A (Fig. 7C). 
It is also important to note that AIP did not affect general trypsin activity, as evidenced by the ratio of 
fragment Aβ 1–16 to uncleaved Aβ 42 which was unaltered in the absence or presence of AIP (Fig. 7D).
Since the Asp23-Lys28 salt bridge appears to be important for AIP to inhibit Aβ 42-mediated tox-
icity, we tested the Aβ 42 D23N Iowa mutation peptide which is associated with progressive AD-like 
dementia, and has been found to be more neurotoxic and to aggregate more rapidly than the wt pep-
tide40. In the Asp-to-Asn mutant, the wild-type Asp23-Lys28 salt bridge cannot form, thus allowing the 
sequence to transform either in parallel or antiparallel β -sheets which alters its folding nucleation41. 
Indeed, elimination of the salt bridge in the Asp23 to Asn substitution peptide abolished the ability of 
AIP to inhibit mature fibril formation as revealed by EM (Fig. 8). Notably, this is fully consistent with our 
best-fit molecular docking poses implying that AIP-Arg1 and its protonated N-terminus make H-bonds 
to Asp23, interfering with the Asp23-Lys28 salt bridge.
Discussion
The current Aβ oligomer hypothesis implies that oligomeric Aβ species are toxic while amyloid plaques/
fibrils are not inherently toxic but a consequence of aberrant Aβ aggregation42. Accordingly, to investigate 
molecular mechanisms of actions that can detoxify these neurotoxic oligomers is important and highly 
desirable. In this study, we have demonstrated in vitro and in vivo that a non-amidated 8-residue peptide 
(RGTFEGKF) can function as a selective and potent Aβ -oligomer Interacting Peptide (AIP). AIP not 
only suppresses aggregation of Aβ oligomers into proto-fibrillar structures, but also neutralizes toxic Aβ 
oligomers. AIP directly influences the self-aggregation and in vivo toxicity of Aβ without leading to an 
obvious disaggregation of amyloid oligomers from fibrils. Oligomers were stable in the presence of excess 
AIP. In this regard, AIP might act as a chaperone, not causing an apparent dissociation of Aβ complexes 
into monomers, but competing with the addition of further monomers or oligomers to effectively pre-
vent the growth of Aβ oligomers into larger assemblies. Compared to previously reported anti-amyloid 
oligomer strategies, AIP is unique in that it is neither a dissociation catalyst nor a monomer competitor 
(e.g antibodies such as crenezumab or solanezumab43) nor an aggregation enhancer (e.g. D-amino pep-
tides such as D344).
Our biophysical data (EM, AFM, SEC) together with limited proteolysis/mass spectrometry results 
demonstrate that AIP directly interacts with Aβ . While the amidated predecessor of AIP was ini-
tially designed on the framework GxFxGxF to disrupt sheet-to-sheet packings of Aβ 40 fibrils26,27, our 
non-amidated AIP can inhibit mature fibril formation, suppress large aggregate formation, and appears to 
specifically interact with Aβ tetramers. In contrast to other small aggregation inhibitors45–47, AIP shows 
that peptide-based compounds can arrest further growth of the aggregates – an important and beneficial 
mode of action. To not only bind pre-existing low-n oligomeric complexes (with varying degrees of tox-
icity and solubility), AIP also may target a multitude of toxic Aβ oligomeric species built from potentially 
Figure 6. L-AIP docked to Aβ42 and to Aβ42 G33A. (A) Representative L-AIP Aβ42 complex 
obtained from flexible docking in stick (full view) or surface representation (inset). (B) Representative 
L-AIP Aβ42 G33A complex obtained from flexible docking in stick (full view) or surface 
representation (inset). In all figures, L-AIP is shown in green sticks with nitrogen colored in blue, 
oxygen in red, and hydrogens of polar side chains in white. Residue labels are marked by thick 
boundary lines. Hydrogen bonds are depicted as black dashed lines. Aβ42 and Aβ42 G33A are shown 
as gray cartoons and sticks, with G33 and G37 colored in red, Ala33 in magenta, Asp23 in black, and 
sulfur atoms of Met35 in yellow. Residue labels are marked by thin boundary lines.
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toxic subunits of Aβ tetramers15,16,48. As demonstrated by our EM and AFM data, co-incubating AIP with 
Aβ inhibits the formation of mature fibrils (ultimately the same outcome as the substitution variant Aβ 42 
G33A alone, as described previously16).
The Aβ 42 G33A tetramer is naturally non-toxic16,49,50 and has a strong tendency to assemble into 
high-n oligomers due to its extended hydrophobic surface patch. The substitution at position 33 may 
Figure 7. Co-incubation of Aβ42 with AIP affects accessibility of Lys28. (A) MALDI-MS spectra of 
tryptic digests yielded the following mass peaks (in Dalton (Da)): Aβ 42 wt, 4512.3; Aβ 17–28, 1325.7; 
Aβ 1–16, 1954.9. (B) MALDI-MS spectra of a 3 hour tryptic digest of L- or D-AIP (941.5). Generation 
of Aβ 17–28 (C) and Aβ 1–16 (D) fragments by limited tryptic digestion of Aβ 42 wt, Aβ 42 G33A with or 
without L- or D-AIP, respectively. The values of the respective fragments were calculated as the ratio of ion 
peak areas of MALDI-MS spectra recorded at different time points. (C) For Aβ 42 wt a rapid generation of 
high amounts of Aβ 17–28 was observed, but hardly any cleavage of trypsin was seen at position Lys28 after 
co-incubation with L- or D-AIP. No difference was observed for Aβ 42 G33A incubated with or without 
L- or D-AIP. (D) The ratios of the fragment Aβ 1–16 generated from Aβ 42 wt or Aβ 42 G33A yielded no 
differences with or without L- or D-AIP, respectively.
Aβ42 D23N Aβ42 D23N + AIP
Figure 8. Aggregation studies of Aβ42 D23N peptides. TEM micrographs were acquired after 24 hours 
incubation. Aβ 42 D23N aggregated to mature fibrils. AIP did not inhibit fibril formation of Aβ 42 D23N. 
Scale bar = 200 nm.
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cause an altered seed structure of Aβ 4251 and substitution variants with either an alanine or isoleucine 
at position G33 of the Aβ sequence showed a lack of Aβ 42-induced neurotoxicity, but an increased 
aggregation of freshly dissolved peptides due to structural differences16,49. Positions Ile31, Gly33 and 
Met35 have an overall higher solvent-excluded surface value and especially shielding of Gly33 leads to an 
enlarged solvent-excluded surface and promotes aggregation16. In the present study, we show that Gly33 
not only impacts the aggregation of freshly dissolved Aβ 42 peptides, it provokes the formation of high-n 
oligomers over time as observed by our SEC studies. However, our EM and AFM data show that Aβ 42 
G33A does not form mature fibrils and, in this regard, its behavior is similar to AIP/Aβ 42 co-incubation.
It has been shown that Aβ 42 oligomers can disrupt LTP in slices and in vivo, and also have the 
potential to impair the memory of a complex learned behavior in rats3,16,17. Furthermore, learning models 
such as LTP have been shown to induce dendritic spine structural modifications52,53, and LTP induc-
tion has been demonstrated to promote spine enlargement and the growth of new spines31,54–57, spine 
branching58, and actin-dependent remodeling59,60. Notably, an increase in spine volume accompanied 
by insertion of AMPA receptors has been observed as well31. Since Aβ 42 low-n oligomers promote the 
progressive loss of dendritic spines and glutamatergic synapses17,18,61, our present study (spine density, 
LTP, and toxicity data combined) clearly demonstrates that AIP can neutralize Aβ 42-induced neurotoxic 
effects. Mechanistically, it is likely that AIP masked the receptor recognition site of Aβ 42 oligomers, e.g., 
the cellular form of the prion protein, which has been suggested as a receptor for Aβ 42 oligomers62. 
Consequently, Aβ 42 “trapped” oligomers would not interact with the putative receptor, which may result 
in non-altered spine morphology and no decreased LTP, as demonstrated in our study.
The Drosophila “rough eye” model has become a well-established system to study toxic events as 
related to human cancers63 and neurodegeneration64. To assess whether the AIP has a protective effect 
against cell-derived Aβ 42, we used our previous Drosophila model where the transgenic expression and 
secretion of Aβ 42 in the eye generates Aβ aggregates16. Transgenic Aβ 42 flies raised on food containing 
D-amino acid AIP exhibited a less severe rough-eye phenotype compared to (i) transgenic Aβ 42 flies 
treated with L-amino acid AIP, or (ii) non-treated transgenic Aβ 42 flies. In addition to its small molec-
ular mass (< 1 kDa), the added protease resistant nature of D-AIP most likely contributed to its superior 
bioavailability and efficacy35,36. Since D-AIP could attenuate Aβ 42-induced toxicity at both structural 
(i.e. significantly improved eye morphology by EM) and functional levels (i.e. significantly ameliorated 
function of photoreceptors by ERG), our findings underscore the potential of the AIP as a new thera-
peutic strategy.
Our in vitro and in vivo results can be explained by the interaction of AIP with the two Aβ 42 sites 
(Gly33 and Asp23) that are critical for fibril growth and modulating toxicity. The molecular docking 
poses indicate that both L- and D-AIP make multiple hydrogen bonds to free backbone amid nitrogens 
or oxygens at the oligomer edges with either polar side chains or the backbone, which further hinders 
Aβ 42 β -sheet attachment. Similarly, others have identified tau residues 306–311 (VQIVYK) as a target 
template for the D-amino acid hexapeptide TLKIVW that can prevent self-interaction of the VQIVYK 
sequence via a steric hindrance65.
The best-fit docking poses for AIP revealed that AIP-Arg1 and its protonated N-terminus make 
H-bonds to Aβ -Asp23, which interferes with the Asp23-Lys28 salt bridge which is important for Aβ 42 
fibril growth. A peptide carrying the familial AD (FAD) mutation Aβ 42 D23N (Iowa), unable to form 
the salt bridge by the substitution of Asp23 to Asn2341, failed to show the inhibitory effect of AIP on 
aggregation. This finding underscores the importance of the intramolecular contact between positions 
Asp23 and Lys28 in the Aβ sequence which alters aggregation and modulates toxicity since this FAD 
mutation has a 2- to 3-fold higher neurotoxicity compared to Aβ 42 wt40. Thus, our data indicate that AIP 
contacts Aβ 42 peptide through the Gly33- or the Gly37-groove and that the altered three-dimensional 
shape between L- and D-forms retained the biological activity of AIP, i.e., by interfering with the salt 
bridge and inhibiting Aβ -induced neurotoxicity.
Numerous molecules have been identified which possess the ability to prevent amyloid fibril forma-
tion, both in vivo and in vitro. These molecules range from large proteins such as molecular chaperones19 
to small molecules such as flavonoids20 to polyphenols21. So far, the most successful structure-based 
approach to prevent fibril formation has been to stabilize the native tetrameric structure of transthyretin 
(TTR)66 in TTR amyloidogenesis. Tafamidis meglumine, a small molecule which binds selectively to 
two normally unoccupied thyroxine-binding sites of the tetramer and kinetically stabilizes TTR through 
hydrophobic and electrostatic interactions67, similar to AIP-Aβ interactions. Although Aβ lacks a fully 
ordered native structure68, this effect proves the concept that stabilization of a native stable confor-
mation can have beneficial outcomes in protein misfolding diseases, i.e., preparing AIP-Aβ complexes 
for removal and efficient clearance. While our present study establishes a clear biological effect of AIP 
on Aβ 42-mediated toxicity, further investigation is needed to determine the exact interaction model 
between AIP-like inhibitors and amyloidogenic peptides for rational therapeutic design.
Methods
Peptides. Synthetic Aβ peptides and AIP were purchased from Peptide Specialty Laboratories, 
Germany, and ChemImpex INT’L INC, USA, respectively. Aβ was monomerized and solubilized as 
described49. Briefly, monomerized peptides were dissolved to 1 mg/ml in deionized water supplemented 
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with ammonia to a final concentration of 0.13% (measured pH 9.8). The AIP was applied at an 
Aβ 42-to-AIP molar ratio of 1:20.
Transmission Electron Microscopy (TEM). Aβ peptides were dissolved to 40 μ M and incubated for 
24 h at room temperature. Aliquots (10 μ l) of matured peptide solutions were applied to glow-discharged 
carbon-coated copper grids, or to formvar-coated nickel grids, respectively, and negatively stained with 
2% aqueous uranyl acetate as described69. Micrographs were taken using a Philips CM100 electron 
microscope at 100 kV and a Fastscan CCD camera (Tietz Video and Image Processing Systems GmbH, 
Gauting, Germany).
Atomic Force Microscopy (AFM). AFM is an appropriate method for the characterization of 
pre-fibrillar protein assemblies. Here, 5 μ l of a 40 μ M Aβ peptide solution were applied on a 0.5 mm2 
freshly cleaved sheet of mica for 10–30 seconds and then removed by fast spinning off. AFM images were 
recorded using a MultiMode scanning probe microscope (either NanoScope IIIa, Digital Instruments 
Inc., or NanoScope IV, Veeco Instruments Inc., Santa Barbara, California, USA), equipped with a 10 μ m 
scanner (E-scanner). Height and phase images were recorded in tapping mode with scan rates of 2–4 
lines per second and a resolution of 512 × 512 pixels. Olympus etched silicon cantilevers were used with 
a typical resonance frequency in the range of 60–80 kHz and a spring constant of 2 N/m. All samples 
were investigated on dry substrates of mica (PLANO W. Plannet GmbH, Wetzlar, Germany) at room 
temperature open to air.
Size exclusion chromatography (SEC). SEC was performed as described16. Briefly, synthetic Aβ 
peptides were dissolved and mixed with or without AIP prior to incubation for 0, 4, or and 8 hours 
at room temperature. Oligomers were separated by a Superose 12 10/300 GL column (GE Healthcare, 
Germany) with PBS as running buffer at a flow rate of 0.5 ml/min.
Limited proteolysis. Proteolysis was performed as described16 with minor modifications. Briefly, 
Aβ 42 peptides were dissolved as described above and diluted in 25 mM ammonium bicarbonate, pH 
7.5 to a concentration of 20 μ g/ml. Aβ peptides were pre-incubated for 4 hours at room temperature 
without and in conjunction with the AIP, respectively. The tryptic digest was performed at 37 °C using 
an enzyme–substrate ratio of 1:500 trypsin (Roche) for up to 3 hours. Fragments were identified by mass 
spectrometry (UltrafleXtreme MALDI-TOF/TOF Bruker Daltonics, Germany) in reflector-positive mode 
using CCA matrix.
Molecular Modeling. A tetrameric Aβ 42 fibril core structure was obtained from the pentameric 
NMR structure 2BEG39 by removing one lateral beta sheet in Pymol. Aβ 42 G33A tetramer was generated 
by point mutating the tetramer Aβ 42 structure at all Gly33 to Ala using Schrödingers maestro 2014–2 
suite (Schrödinger Release 2014–2: Maestro, version 9.8, Schrödinger, LLC, New York, NY, 2014). For 
docking, both structures were prepared with the Protein Preparation Wizard70.
A docking grid suitable for peptide docking was generated with its centre (10 Å) between the middle 
of two Met35, defining the center of all Gly/Ala33, Met35 and Gly37 residues by means of the recep-
tor grid generator. This defines a binding site large enough for binding of the AIP ligand (with length 
< 36 Å). The AIP was built as random coil in Pymol with charged Arginine, Glutamic acid and Lysine 
side chains and termini. Maestros build utility was used to generate its D-enantiomer (D-AIP). Both 
ligands were prepared with the LigPrep Wizard (LigPrep, version 3.0, Schrödinger, LLC, New York, 
NY, 2014) for the forcefield OPLS_200571 including Epik protonation states72 and including the original 
state for neutral pH 7 ± 0.5 (covering physiological pH 7.4). Glide SP-peptide docking for flexible ligand 
sampling73 was performed using standard settings and specifically sampling nitrogen inversions, ring 
conformations (including input conformation), no bias sampling of torsions, and enhanced planarity of 
conjugated pi groups. The docking score was modified by Epik state penalties. The SP-peptide docking 
protocol yields around 119–200 poses per run with no more than 5–19 reasonable < -5  kcal/mol and 
1–4 best docking scores < -7 kcal/mol.
Toxicity on primary hippocampal neurons and neuroblastoma cells. Primary neurons were 
prepared as previously described16. Briefly, hippocampi of postnatal day 0 (P0)–P1 Wistar rat pups 
were dissociated and cultured in neurobasal A medium. After 10 days in vitro, Aβ 42 (2.5 μ M) peptides 
were pre-incubated (4 or 24 hours) in the presence and absence of the AIP, respectively. Neuronal cul-
tures were treated with the pre-incubated peptides for 48 hours. Neuronal viability was detected using the 
MultiTox-Fluor Multiplex Cytotoxicity assay (Promega, Germany), performed according to manufacturer’s 
instructions.
To determine Aβ toxicity in SH-SHY5 cells, the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl- 
tetrazolium bromide) assay was performed as described49. Aβ peptides were applied at a concentration 
of 2.5 μ M for 12 hours.
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Organotypic hippocampal slice cultures, image acquisition and quantification of dendritic 
spines. Hippocampal slices (400 μ m) from P6–8 transgenic mice expressing membrane-targeted 
MARCKS-eGFP under the Thy-1 promoter in a subpopulation of CA1 cells74 were prepared as previ-
ously described using the roller-tube method75. Slice cultures were maintained in the incubator with a 
roller-drum for three weeks before experimentation to allow for spine maturation76. Slices were incu-
bated with or without 1 μ M Aβ 42 peptide and 20 μ M AIP-containing media for 24 hours. Image acqui-
sition and quantification was performed as described76. Briefly, following treatment, slice cultures were 
transferred to a temperature-controlled chamber (30 °C) mounted on an upright confocal microscope 
and continuously perfused with Tyrode solution. Secondary and tertiary dendritic branches from either 
apical or basal dendrites of CA1 pyramidal neurons were imaged.
All animal handling procedures were carried out in accordance with guidelines set by the Canadian 
Council on Animal Care and the National Institutes of Health in the USA. All procedures were approved 
by the Animal Resource Committee of the School of Medicine at McGill University, and are outlined in 
McGill University Animal Handling Protocol #5057.
fEPSP recordings and Long Term Potentiation. fEPSPs were recorded in the CA1 stratum oriens 
at 30 °C as previously described76 with minor modifications. Briefly, a surgical cut was made between 
CA3 and CA1. Schaffer collateral axons were then stimulated with an insulated platinum–iridium bipolar 
electrode. The stimulus strength was between 40 μ A and 200 μ A, to achieve one-half to one-third of the 
maximum response, and stimulation was provided every 10 s. Data points were then pooled and averaged 
into five minute intervals for statistical analysis and graphical display in the figures. LTP was induced 
with a TBS paradigm consisting of bursts of five pulses at 100 Hz; the bursts were applied five times at 
intervals of 200 ms, and delivered five times every 10 s. Slices were treated with freshly-dissolved 1 μ M 
Aβ 42 peptide, 20 μ M AIP, or 1 μ M Aβ 42 peptide and 20 μ M AIP-containing media for 24 hours prior 
to recordings.
Eye structure analysis of D. melanogaster. UAS-Aβ 42 flies were generated as previously described16. 
Briefly, transgenic flies harboring UAS-Aβ 42 were crossed with flies containing GMR-GAL4 to achieve 
eye-specific Aβ 42 expression. Flies were bred on Jazz-Mix Drosophila fly food (Fisher Scientific, USA) 
containing 5 mM L-AIP or D-AIP, respectively. Five-day-old flies were collected and analyzed. Fly eyes 
were fixed in 2.5% glutaraldehyde, 2% formaldehyde in 100 mM PB buffer, pH 7.4, post-fixed in 1.5% 
osmium tetroxide. Samples were embedded in epon and polymerized at 60 °C for at least 48 hours. The 
sections were counterstained with aqueous uranyl acetate followed by lead citrate. Micrographs were 
taken using a Philips CM120 electron microscope at 80 kV and a 1 K CCD camera.
Electroretinography. Flies were immobilized inside the end of a plastic pipette tip. The ERGs were 
recorded using borosilicate pipette microelectrode in contact with the eye, and a reference tungsten 
electrode inserted into the abdomen. The microelectrode was filled with artificial cerebral-spinal fluid 
containing: 115 mM NaCl, 5 mM KCl, 23 mM glucose, 26 mM sucrose, 4.2 mM HEPES, 2.5 mM CaCl2, 
and 1.3 mM MgCl2, pH 7.2. Signals were amplified and filtered (1 kHz) using an Axopatch 200B amplifier, 
sampled at 5 kHz using a Digidata 1440A, and recorded with Clampex 10.3 (Molecular Devices). Blue 
light from a LUXEON®Star LED with a dominant wavelength of 470 nm was delivered to the fly head via 
an optical fiber cable 5 cm from the fly head. Light stimulus was driven by a Thor labs LEDD1B controller 
with stimulus of 1000 ms. Representative traces were low bandpass filtered.
Statistical Analyses. All results are expressed as means ± SEM (Standard Error of Mean). Statistical 
comparisons were made by either unpaired Student’s t-test, or by One-way ANOVA followed by 
Tukey-Kramer or Dunnett’s post hoc test to identify differences between treatments. All data presented 
are from a minimum of three independent experiments. P values < 0.05 were considered significant: 
*p < 0.05, **p < 0.01; ***p < 0.001.
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